HLS Therapeutics Inc. (HLS.TO)
| Previous Close | 4.6500 |
| Open | 4.6500 |
| Bid | 4.3000 x 0 |
| Ask | 4.7500 x 0 |
| Day's Range | 4.6500 - 4.6500 |
| 52 Week Range | 3.3400 - 7.1200 |
| Volume | |
| Avg. Volume | 9,760 |
| Market Cap | 148.271M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1600 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | 0.20 (4.30%) |
| Ex-Dividend Date | Apr 27, 2023 |
| 1y Target Est | 6.71 |
CNW GroupHLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday, May 9, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. John Hanna, Interim Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
- Baystreet
Stocks in play: HLS Therapeutics Inc.
Announces that Chief Executive Officer Craig Millian will present at the Bloom Burton & Co. Healthcare ...
CNW GroupHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Craig Millian, Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference, which takes place April 16-17, 2024 at the Metro Toronto Convention Centre, North Building, in downtown Toronto.
